Treating neuropathic pain in cancer

Harman, Stephanie
August 2009
Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p34
The article presents information on the treatment of neuropathic pain in patients diagnosed with cancer.


Related Articles

  • Management of Pain in Patients with Cancer. Miller, Karl E. // American Family Physician;2/1/2000, Vol. 61 Issue 3, p835 

    Discusses research on management of pain in cancer patients. Reference to a study by J. L. Abrahm, from the July 6, 1999 issue of the `Annals of Internal Medicine'; Problems of pain and spinal cord compression experienced by cancer patients; Assessment of pain intensity; Prescription of opioids...

  • Coeliac plexus block for upper abdominal cancer pain. Chambers, Pauline C. // British Journal of Nursing;7/24/2003, Vol. 12 Issue 14, p838 

    Examines the use of celiac plexus block to relieve intractable pain due to upper abdominal cancer. Percentage of patients reporting significant relief, allowing a reduction in opioid use and the occurrence of opioid-related side effects; Variations in the duration of relief.

  • The challenges of cancer pain assessment and management. Campbell, Victoria // Ulster Medical Journal;May2011, Vol. 80 Issue 2, p104 

    The article focuses on the challenges in assessing and managing cancer pain which is present in 36 to 61 percent of patients. Assessment is the first step to pain management which involves detailed history and physical examination, psychosocial assessment and a diagnostic work-up. Cancer pain...

  • Management of cancer pain: ESMO Clinical Recommendations. Jost, L.; Roila, F. // Annals of Oncology;May2009 Supplement 4, Vol. 20, piv170 

    The article presents clinical recommendations for the management of cancer pain from the European Society for Medical Oncology (ESMO). The incidence of pain is based on the fact that over 80 percent of cancer patients with advanced metastatic disease suffer pain due to direct tumor infiltration....

  • OROS Hydromorphone Prolonged Release. Carter, Natalie I.; Keating, Gillian M. // CNS Drugs;2010, Vol. 24 Issue 4, p337 

    OROS® hydromorphone prolonged release (OROS® hydromorphone) [Jurnista™] is a once-daily formulation of the opioid agonist hydromorphone that utilizes OROS® (osmotic-controlled release oral delivery system) technology to deliver the drug at a near constant rate, thereby providing...

  • Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Rauck, R.; North, J.; Gever, L. N.; Tagarro, I.; Finn, A. L. // Annals of Oncology;Jun2010, Vol. 21 Issue 6, p1308 

    Background: Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer. The objective of this study was to evaluate the efficacy of FBSF at doses of 200–1200 μg in the management of breakthrough pain in patients...

  • Cancer pain management in children. Mercadante, Sebastiano // Palliative Medicine;Nov2004, Vol. 18 Issue 7, p654 

    Unrelieved pain may have a major impact on the care of children with cancer. The type and severity of pain experienced by children with cancer varies from acute, procedure-related pain to progressive chronic pain associated with the progression of the disease or sequelae of treatment. Drugs are...

  • The Other Side of the Opioid Story: Modulation of Cell Growth and Survival Signaling. Chen, Yulong L.; Ping Yee Law; Loh, Horace H. // Current Medicinal Chemistry;2008, Vol. 15 Issue 8, p772 

    Opioids have been used as pain control medications for thousands of years. Opioids are highly effective analgesics clinically available for controlling moderate and severe pain. Recent genetic knockout and knockin studies have definitively demonstrated that the analgesic effect is mediated...

  • Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate. Vasisht, Niraj; Gever, Larry N.; Tagarro, Ignacio; Finn, Andrew L. // Clinical Drug Investigation;2009, Vol. 29 Issue 10, p647 

    Background and Objectives: BioErodible MucoAdhesive (BEMA®) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses this novel delivery system contains fentanyl and is intended for the treatment of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics